150 Years of Fighting Fraud – The False Claims Act’s Growing Reach and Increased Enforcement

150 Years of Fighting Fraud – The False Claims Act’s Growing Reach and Increased Enforcement

facebooktwittergoogle_plusredditlinkedinmail
One of the US government’s most versatile legal weapons to fight fraud, the False Claims Act is now more powerful and has a wider scope than ever before. In recent years, the US government has used the law to aggressively pursue health care fraud cases against pharmaceutical companies and healthcare providers, as well as targeting major financial institutions for mortgage fraud.

The rise in FCA enforcement has created new compliance risks for a whole range of companies, while encouraging whistleblowers with the potential for multi-million dollar rewards. This ACFCS webinar, presented by two leading experts and attorneys with combined experience in FCA cases of nearly twenty-five years, dissects the key provisions and rising use of the law. It will provide guidance on where the Justice Department is focusing its FCA enforcement efforts, when and how private citizens use the law to bring their own civil suits, and what steps companies should take to avoid running afoul of the FCA.

Attendees will learn:

  • An overview of the False Claims Act and its legal provisions
  • How the FCA is employed by the US government
  • How private citizens can pursue FCA cases even if the government declines
  • Case studies of significant recent FCA cases in the health care and mortgage fraud fields
  • How and why FCA cases have increased since the 2009 amendments
  • Best practices for compliance and guidance on preventing FCA cases

 

About the Presenters:

GreeneThomas M. Greene has practiced complex civil litigation for more than thirty years, representing plaintiffs. Since 1992, he represented whistleblowers under the False Claims Act. In a seminal lawsuit against Parke-Davis and Pfizer, a case which involved off-label promotion of the drug Neurontin, Mr. Greene established for the first time that off-label promotion of drugs could lead to actionable false claims under the False Claims Act. Mr. Greene specializes in False Claims Act litigation, and has pursued whistleblower cases in the pharmaceutical, health care, import, and financial industries.

MorrisonRyan P. Morrison is a Greene LLP associate who has specialized in litigating False Claims Act cases since joining the firm in 2010. He has acted as a bankruptcy and securities law expert for a CPA exam review company, and was a research assistant to Professor Daniel Coquillette, Reporter to the Committee on Rules of Practice and Procedure, Judicial Conference of the United States. Mr. Morrison currently represents whistleblowers in a wide variety of False Claims Act cases, from large-scale health care and banking cases to customs, postal, and public utilities cases. [/private]